Speaking of horse races; the following *Top Ten* Pharmaceutical companies are in their stalls.
Place your bets gentlefolk...who stands to lose the MOST in the {ONCOLOGY} Race.
Roche: Winnings for year $25,659,000,000. {39.72 %} of Total revenues and SP = $369.20
Celgene: " " " $23,969,000,000 {56.37 %} of Total revenues and SP = $108.24
BMS buys Celgene for $95Billion BMS SP = $ 63.94
Novartis: " " " $11,811,000,000. {24.30 %}of Total revenues and SP = $ 87.41
J and J: " " " $ 9,844,000,000. {11.92 %} of Total revenues and SP = $164.93
Merck: " " " $ 8,243,000,000 {17.18 %} of Total revenues and SP = $ 77.39
Pfizer: " " " $ 7,202,000,000 {17.18 %} of Total revenues and SP = $ 36.25
AstraZ: " " " $ 6,028,000,000 {22.64 %} of Total revenues and SP = $ 50.64
Lilly: " " " $ 4,260,000,000 {17.36 %} of Total revenues and SP = $ 183.09
ABBvie: " " " $ 3,934,000,000 { 8.59 % }of Total revenues and SP = $ 105.98

Global ONCOLOGY Market is expected to be worth $202.54 BILLIONS by 2023
So with everyone chomping on the bit...and WE are the dark horse..WHO should be worried?

,